Oryzon Genomics - Preclinical collaboration in orphan disease
Oryzon Genomics has announced that it is has entered into a partnership with the Charcot-Marie-Tooth Research Foundation (CMTRF). The collaboration will investigate the use of Oryzon’s preclinical histone deacetylase 6 (HDAC6) inhibitors for the treatment of Charcot-Marie-Tooth (CMT) disease, a rare neurodegenerative disease with no curative or symptomatic medications approved for treatment. Under the terms of the partnership, the CMTRF will fund preclinical development for a series of in vivo studies to assess two of Oryzon’s most promising HDAC6 candidates. The financing and development support from the CMTRF, we believe, could potentially expedite the progression of Oryzon’s HDAC6 assets towards clinical development, which would represent a future catalyst for share price.Oryzon Genomics SA is a Spain-based biopharmaceutical company. It is engaged in the field of epigenetic medicine and in the development of therapeutic, biological solutions for cancer and neurodegenerative diseases. The Company's business model focuses on identifying biomarkers that can be translated in new therapeutic targets, as well as on investing in programs, mainly through the development of small molecules for two main indications: cancer and neurodegeneration. The Company develops investigational medicines till proof of concept (POC) phase and then partners the program with pharmaceutical entities, which are able to get the approval from drug agencies to bring these medicines to the patients. It cooperates with Roche. The Company is a subsidiary of Laboratorio Reig Jofre SA.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.